US BANCORP \DE\ - NEKTAR THERAPEUTICS ownership

NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 216 filers reported holding NEKTAR THERAPEUTICS in Q4 2022. The put-call ratio across all filers is 0.90 and the average weighting 0.0%.

Quarter-by-quarter ownership
US BANCORP \DE\ ownership history of NEKTAR THERAPEUTICS
ValueSharesWeighting
Q3 2023$30,346
+3.5%
50,9500.0%0.00%
Q2 2023$29,306
-30.1%
50,950
-14.5%
0.00%
Q1 2023$41,906
-70.0%
59,610
-3.6%
0.00%
Q4 2022$139,779
-35.0%
61,849
-7.6%
0.00%
Q3 2022$215,000
-18.6%
66,968
-3.6%
0.00%
-100.0%
Q2 2022$264,000
-79.0%
69,495
-70.3%
0.00%
-50.0%
Q1 2022$1,260,000
-59.8%
233,836
+0.7%
0.00%
-60.0%
Q4 2021$3,137,000
-29.4%
232,218
-6.1%
0.01%
-37.5%
Q3 2021$4,443,000
-4.2%
247,362
-8.5%
0.01%
-11.1%
Q2 2021$4,638,000
-13.9%
270,263
+0.4%
0.01%
-18.2%
Q1 2021$5,386,000
+15.2%
269,294
-2.1%
0.01%
+10.0%
Q4 2020$4,676,000
+49.1%
275,024
+45.4%
0.01%
+25.0%
Q3 2020$3,137,000
+54.0%
189,103
+114.9%
0.01%
+60.0%
Q2 2020$2,037,000
+29.5%
87,981
-0.2%
0.01%0.0%
Q1 2020$1,573,000
-16.8%
88,121
+0.6%
0.01%0.0%
Q4 2019$1,891,000
+18.3%
87,614
-0.1%
0.01%
+25.0%
Q3 2019$1,598,000
-48.8%
87,704
-0.1%
0.00%
-55.6%
Q2 2019$3,124,000
+6.7%
87,784
+0.7%
0.01%
+12.5%
Q1 2019$2,929,000
+2.2%
87,202
+0.0%
0.01%
-11.1%
Q4 2018$2,865,000
-46.1%
87,165
+0.0%
0.01%
-40.0%
Q3 2018$5,314,000
+24.8%
87,159
-0.0%
0.02%
+15.4%
Q2 2018$4,257,000
-54.1%
87,194
-0.2%
0.01%
-53.6%
Q1 2018$9,282,000
+78.0%
87,350
+0.0%
0.03%
+75.0%
Q4 2017$5,216,000
+132.9%
87,340
-6.4%
0.02%
+128.6%
Q3 2017$2,240,000
+22.7%
93,3400.0%0.01%
+16.7%
Q2 2017$1,825,000
-16.7%
93,3400.0%0.01%
-25.0%
Q1 2017$2,191,000
+91.4%
93,3400.0%0.01%
+100.0%
Q4 2016$1,145,000
-29.1%
93,340
-0.7%
0.00%
-33.3%
Q3 2016$1,615,000
+21.6%
94,005
+0.7%
0.01%
+20.0%
Q2 2016$1,328,000
+3.4%
93,3400.0%0.01%0.0%
Q1 2016$1,284,000
-18.4%
93,3400.0%0.01%
-16.7%
Q4 2015$1,573,000
+50.1%
93,340
-2.3%
0.01%
+50.0%
Q3 2015$1,048,000
-11.9%
95,507
+0.4%
0.00%
-20.0%
Q2 2015$1,190,000
+13.7%
95,1670.0%0.01%
+25.0%
Q1 2015$1,047,000
-27.4%
95,167
+2.3%
0.00%
-33.3%
Q4 2014$1,442,000
+21.1%
93,000
-5.8%
0.01%
+20.0%
Q3 2014$1,191,000
-8.0%
98,736
-2.3%
0.01%0.0%
Q2 2014$1,295,000
+62.7%
101,041
+53.8%
0.01%
+66.7%
Q1 2014$796,000
+12.7%
65,715
+5.6%
0.00%0.0%
Q4 2013$706,000
+49.3%
62,237
+37.5%
0.00%
+50.0%
Q3 2013$473,000
+307.8%
45,248
+352.5%
0.00%
+100.0%
Q2 2013$116,00010,0000.00%
Other shareholders
NEKTAR THERAPEUTICS shareholders Q4 2022
NameSharesValueWeighting ↓
Cormorant Asset Management, LP 1,828,400$89,281,0006.61%
Cormorant Asset Management, LP 1,500,000$73,245,0005.42%
Camber Capital Management LP 2,000,000$97,660,0003.76%
Rhenman & Partners Asset Management AB 617,652$30,160,0003.09%
BRIDGER MANAGEMENT, LLC 1,134,414$55,393,0003.00%
First Light Asset Management, LLC 374,251$18,275,0002.84%
Gs Investments, Inc. 54,000$2,636,820,0001.97%
SABBY MANAGEMENT, LLC 241,922$11,813,0001.82%
QUANTRES ASSET MANAGEMENT Ltd 50,000$2,441,0001.41%
Tibra Equities Europe Ltd 173,183$8,457,0001.27%
View complete list of NEKTAR THERAPEUTICS shareholders